Drugs / Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00909558 | May 2009 → Jun 2010 | breast cancer, colon carcinoma, glioma, hepatocellular carcinoma +3 | Envita Medical Center, Inc. | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Natural Killer / Natural Killer T Cell Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00909558 ↗ |
| Modality | Cell therapy | “natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy” NCT00909558 ↗ |